Testing of Compounds for Off-Target Activity in a Broad Panel of Safety-Related Targets
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95019Q00111 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition teshold. The Government anticipates award of a firm fixed-price purchase order for this acquisition. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Eurofins Panlabs Discovery Services Taiwan, Ltd., 25, Wugong 6th Rd., Wugu District, New Taipei City, 24891, TAIWAN for full panel 174 safety-related targets compound testing. This acquisition is conducted as non-competitive for a commercial service and is conducted pursuant to FAR 13.106-1(b)(1). The rationale for this sole single-source justification is: the contractor must have significant experience (more than 5 years) in the testing of small molecule compounds for binding activity in a panel of at least 174 safety-related targets, specifically the ion channel, GPCR and enzyme targets that are listed in the Statement of Work (SOW) for this request. Significant experience in running these assays is required so that the data obtained may be judged to be reliable. To NCATS knowledge, this is the only available source that offers reliable testing against the full panel of 174 targets. (iii) The solicitation document and incorporated provisions and clauses are those in effect tough Federal Acquisition Circular (FAC) Number 2019-01, with effective date January 22, 2019. (iv) The associated NAICS code is 541380 and the small business size standard is $15 million. This requirement has no set-aside restrictions. (v) This requirement is for the following services: Testing of 5 novel small molecule compounds in a broad panel of 174 safety-related biological targets. Such testing will inform on the activity of these compounds at critical, safety-related biological targets, and will help predict safety-related adverse events that might occur as compounds are advanced into the clinic. (vi) See Attachment 1, SOW, for a full description of the services including background, purpose, and objectives; general scope of work; contractor's requirements and tasks to be performed; deliverable and reporting requirements; and government's responsibilities. (vii) The Period of performance is within tee (3) months from the contract award and receipt of first batch of material. (viii) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Oct 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (Jul 2016) FAR 52.212-1, Instructions to Offerors-Commercial Items (Oct 2018) FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Oct 2018) FAR 52.225-4, Buy American-Free Trade Agreements-Israel Trade Act Certificate (May 2014)-Alternate III (May 2014) HHSAR 352.239-73, Electronic and Information Technology Accessibility Notice (December 18, 2015) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Jul 2016) FAR 52.212-4, Contract Terms and Conditions-Commercial Items (Oct 2018). Addendum to this FAR clause applies to this acquisition and is attached. HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) The following provisions and clauses apply to this acquisition and are attached in full text: FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items (Oct 2018) NIH Invoice and Payment Provisions (2/2014) (ix) The Government will perform a comparative evaluation of responses in accordance with FAR 13.106-2(b)(3) and award a purchase order from this solicitation to the responsible offeror whose response meets the solicitation's requirements and, as a whole, will be most advantageous to the Government, price and other factors considered. The comparative evaluation will include: Technical Capability of the services to meet the Government requirement, Price, Terms and Conditions, and Past Performance. Responses may exceed capability or performance characteristics of the solicitation's requirements. The Government reserves the right, but is not required, to award to a response that exceeds capability or performance characteristics of the solicitation's requirements if it provides a benefit to the Government. (x) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer. (xi) The clause at FAR 52.212-4, Contract Terms and Conditions-Commercial Items, applies to this acquisition. Addendum to this FAR clause applies to this acquisition and is attached. (xii) The clause at FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition and is attached in full text. (xiii) There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xiv) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xv) Responses to this solicitation must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price quotation must include all applicable costs and be for a firm fixed-price total amount. The Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All quotations must be received by 05:00 p.m., Eastern Daylight Time, on Monday, April 22, 2019, and reference Solicitation Number 75N95019Q00111. Responses must be submitted electronically to Mark McNally, Contract Specialist, at mark.mcnally@nih.gov. Fax responses will not be accepted. (xvi) The name and telephone number of the individual to contact for information regarding the solicitation: Mark McNally, Contract Specialist, 301-827-5869, mark.mcnally@nih.gov. 75N95019Q00111 Department of Health and Human Services National Institutes of Health
4/15/19, 5:16 PM Testing of Compounds for Off-Target Activity in a Broad Panel of Safety-Related Targets
This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) was officially established in fiscal year 2012 to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS, one of 27 Institutes and Centers (ICs) at NIH, strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. Prior work at NCATS has produced a series of small molecule IRAK4 / FLT3 kinase dual inhibitors, including NCGC00371481 and its structural analogs. Compounds such as '1481 have shown promising results in cellular and mouse models of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Further optimization of the biochemical, physiochemical and pharmacokinetic properties of these compounds is required, and may eventually produce a clinical candidate that could be used to treat cancers such as MDS and / or AML. On a separate but related program, prior work at NCATS has led to the discovery of novel small molecule inhibitors of the kinase enzymes LATS1 and LATS2. Inhibitors of these targets may be useful in wound healing, tissue regeneration, and other related areas. In order to fully assess and optimize the biological properties of compounds on these two programs, NCATS needs to understand not only their 'on-target activity' (that is, their inhibition of the desired targets mentioned above), but also their 'off-target activity', meaning any undesired activity at other biological targets. In particular, NCATS needs to understand if they have significant activity at off-targets that are important for safety. By monitoring potential activity at these targets in vitro, NCATS can predict the occurrence of safety-related adverse events that might occur once compounds are advanced into clinical testing. This data will thus help NCATS to identify and ultimately optimize out any unwanted activity, thus allowing NCATS to prioritize the safest compounds for advancement into the clinic. Testing of five (5) small molecule compounds against a broad panel of 174 safety-related targets will allow NCATS to prioritize safer compounds for ultimate advancement into human clinical trials. Purpose and Objectives: The purpose of this acquisition is the testing of five (5) novel small molecule compounds in a broad panel of 174 safety-related biological targets. Such testing will inform on the activity of these compounds at critical, safety-related biological targets, and will help predict safety-related adverse events that might occur as compounds are advanced into the clinic. Project Requirements: Responses must demonstrate capability of meeting the following requirements: 1. Perform experiments using established binding assays testing each of five (5) small molecule compounds for activity against at least 174 safety-related targets, including all of the following GPCR, enzyme and ion channel targets: A1 Human Adenosine GPCR Binding (Antagonist Radioligand) Assay A2A Human Adenosine GPCR Binding (Agonist Radioligand) Assay A2B Human Adenosine GPCR Binding (Antagonist Radioligand) Assay A3 Human Adenosine GPCR Binding (Agonist Radioligand) Assay Adenosine Guinea Pig Transporter Binding (Antagonist Radioligand) Assay alpha1A Rat Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay alpha1B Rat Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay alpha1D Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay alpha2A Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay alpha2B Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay alpha2C Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay beta1 Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay beta2 Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay beta3 Human Adrenoceptor GPCR Binding (Antagonist Radioligand) Assay NET Human Norepinepine Transporter Binding (Antagonist Radioligand) Assay MCR Human Aldosterone NHR Binding (Agonist Radioligand) Assay AR Human Androgen NHR Binding (Agonist Radioligand) Assay AT1 Human Angiotensin GPCR Binding (Agonist Radioligand) Assay AT2 Human Angiotensin GPCR Binding (Agonist Radioligand) Assay APJ Human Apelin GPCR Binding (Agonist Radioligand) Assay Atrial Natriuretic Factor (ANF, Non-Selective) Guinea Pig Binding Assay BB1 Human Bombesin GPCR Binding (Agonist Radioligand) Assay BB2 Human Bombesin GPCR Binding (Agonist Radioligand) Assay BB3 Human Bombesin GPCR Binding (Agonist Radioligand) Assay B1 Human Bradykinin GPCR Binding (Agonist Radioligand) Assay B2 Human Bradykinin GPCR Binding (Agonist Radioligand) Assay CGRP (CLR/RAMP1) Human Calcitonin GPCR Binding (Agonist Radioligand) Assay Cav1.2 (L-type) Rat Calcium Ion Channel Binding (Diltiazem Site) Assay Cav1.2 (L-type) Rat Calcium Ion Channel Binding (Dihydropyridine Site) Assay Cav1.2 (L-type) Rat Calcium Ion Channel Binding (Verapamil Site) Assay Cav2.2 (N-type) Rat Calcium Ion Channel Binding (Antagonist Radioligand) Assay CB1 Human Cannabinoid GPCR Binding (Antagonist Radioligand) Assay CB2 Human Cannabinoid GPCR Binding (Agonist Radioligand) Assay CCR1 Human Chemokine GPCR Binding (Agonist Radioligand) Assay CCR2 Human Chemokine GPCR Binding (Agonist Radioligand) Assay CCR5 Rhesus Macaque Chemokine GPCR Binding (Agonist Radioligand) Assay CCK1 (CCKA) Human Cholecystokinin GPCR Binding (Antagonist Radioligand) Assay CCK2 (CCKB) Human Cholecystokinin GPCR Binding (Agonist Radioligand) Assay CHT1 Rat Choline Transporter Binding (Antagonist Radioligand) Assay Rat Tubulin [3H] Colchicine Binding Assay CRF1 Human Corticotropin-Releasing Factor GPCR Binding (Agonist Radioligand) Assay D1 Human Dopamine GPCR Binding (Antagonist Radioligand) Assay D2S Human Dopamine GPCR Binding (Antagonist Radioligand) Assay D3 Human Dopamine GPCR Binding (Antagonist Radioligand) Assay D4.2 Human Dopamine GPCR Binding (Antagonist Radioligand) Assay D5 Human Dopamine GPCR Binding (Antagonist Radioligand) Assay DAT Human Dopamine Transporter Binding (Antagonist Radioligand) Assay ETA Human Endothelin GPCR Binding (Agonist Radioligand) Assay ETB Human Endothelin GPCR Binding (Agonist Radioligand) Assay EGFR Human RTK Kinase Binding (Agonist Radioligand) Assay ERalpha Human Estrogen NHR Binding (Agonist Radioligand) Assay ERbeta Human Estrogen NHR Binding (Agonist Radioligand) Assay GABA (Non-Selective) Rat Transporter Binding (Antagonist Radioligand) Assay Non-Selective Rat GABAA Ion Channel [3H] Muscimol Binding (Agonist Radioligand) Assay Non-Selective Rat GABAA Ion Channel [3H] Flunitrazepam Binding (Agonist Radioligand) Assay Non-Selective Rat GABAA Ion Channel [3H] TBOB Binding (Antagonist Radioligand) Assay GABAB (B1a/B2) Human GABAB GPCR Binding (Antagonist Radioligand) Assay GABAB (B1b/B2) Human GABAB GPCR Binding (Antagonist Radioligand) Assay Rat Cortex [3H] Gabapentin Binding Assay GHB Rat Binding (Antagonist Radioligand) Assay Glucagon Human Glucagon GPCR Binding (Agonist Radioligand) Assay GR Human Glucocorticoid NHR Binding (Agonist Radioligand) Assay Glutamate (AMPA, Non-Selective) Rat Ion Channel [3H] AMPA Binding Assay Glutamate, Kainate Glutamate (NMDA, Non-Selective) Rat Ion Channel [3H] CGP-39653 Binding Assay Glutamate, NMDA, Glycine [3H] MDL 105,519 Binding Assay Glutamate (Non-Selective) Rat Ion Channel [3H] TCP Binding Assay Glutamate (NMDA, Non-Selective) Rat Ion Channel [3H] Ifenprodil Binding Assay mGlu2 Human Glutamate (Metabotropic) GPCR Binding (Antagonist Radioligand) Assay mGlu5 Human Glutamate (Metabotropic) GPCR Binding (Agonist Radioligand) Assay Non-Selective Rat Glycine Ion Channel [3H] Strychnine Binding Assay GLYT1 Rat Glycine Transporter Binding (Antagonist Radioligand) Assay GnRH Human Gonadotrophin-Releasing Hormone GPCR Binding (Agonist Radioligand) Assay GHSR Human Gelin GPCR Binding (Agonist Radioligand) Assay H1 Human Histamine GPCR Binding (Antagonist Radioligand) Assay H2 Human Histamine GPCR Binding (Antagonist Radioligand) Assay H3 Human Histamine GPCR Binding (Agonist Radioligand) Assay Imidazoline I2, Central Rat Binding (Antagonist Radioligand) Assay IP3R1 Rat IP3 Ion Channel Binding (Agonist Radioligand) Assay IR Rat RTK Kinase Binding (Agonist Radioligand) Assay Interleukin IL-1 R1 IL-6 Human Binding (Agonist Radioligand) Assay CXCR2 (Non-Selective) Human Chemokine GPCR Binding (Agonist Radioligand) Assay CXCR2 (IL-8RB) Human Chemokine GPCR Binding (Agonist Radioligand) Assay CXCR3 Human Chemokine GPCR Binding (Agonist Radioligand) Assay CXCR4 Human Chemokine GPCR Binding (Agonist Radioligand) Assay CX3CR1 Human Chemokine GPCR Binding (Agonist Radioligand) Assay CysLT1 Human Leukotriene GPCR Binding (Agonist Radioligand) Assay BLT1 (LTB4) Human Leukotriene GPCR Binding (Agonist Radioligand) Assay MCH1 Human Melanin-Conc. Hormone GPCR Binding (Agonist Radioligand) Assay MC1 Human Melanocortin GPCR Binding (Agonist Radioligand) Assay MC3 Human Melanocortin GPCR Binding (Agonist Radioligand) Assay MC4 Human Melanocortin GPCR Binding (Agonist Radioligand) Assay MC5 Human Melanocortin GPCR Binding (Agonist Radioligand) Assay MT1 Human Melatonin GPCR Binding (Agonist Radioligand) Assay MT2 Human Melatonin GPCR Binding (Agonist Radioligand) Assay VMAT (Non-Selective) Human Vesicular Monoamine Transporter Binding Assay Motilin Human Motilin GPCR Binding (Agonist Radioligand) Assay M1 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay M2 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay M3 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay M4 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay M5 Human Acetylcholine (Muscarinic) GPCR Binding (Antagonist Radioligand) Assay Non-Selective Rat Acetylcholine (Muscarinic) GPCR Binding (Agonist Radioligand) Assay NK1 Human Tachykinin GPCR Binding (Agonist Radioligand) Assay NK2 Human Tachykinin GPCR Binding (Antagonist Radioligand) Assay NK3 Human Tachykinin GPCR Binding (Agonist Radioligand) Assay Y1 Human Neuropeptide Y GPCR Binding (Agonist Radioligand) Assay Y2 Human Neuropeptide Y GPCR Binding (Agonist Radioligand) Assay NT1 Human Neurotensin GPCR Binding (Agonist Radioligand) Assay nAChR Human Acetylcholine (Nicotinic) Ion Channel Binding Assay nAChR (alpha7) Rat Ion Channel Binding (Antagonist Radioligand) Assay nAChR (alpha7) Human Ion Channel [3H] Methyllycaconitine Binding Assay nAChR (alpha1) Human Ion Channel Binding (Antagonist Radioligand) Assay nAChR (alpha4/beta2) Rat Ion Channel Binding (Agonist Radioligand) Assay delta (DOP) Human Opioid GPCR Binding (Antagonist Radioligand) Assay kappa (KOP) Human Opioid GPCR Binding (Antagonist Radioligand) Assay mu (MOP) Human Opioid GPCR Binding (Antagonist Radioligand) Assay NOP (ORL1) Human Opioid GPCR Binding (Agonist Radioligand) AssayHuman Vasopressin / Oxytocin GPCR Binding (Agonist Radioligand) Assay Phorbol Ester Binding Assay PAF Human Platelet-Activating Factor GPCR Binding (Agonist Radioligand) Assay PDGFR (Non-Selective) Mouse RTK Kinase Binding (Agonist Radioligand) Assay KV (Non-Selective) Rat Potassium Ion Channel [125I] alpha-Dendrotoxin Binding Assay KATP Hamster Potassium Ion Channel Binding (Antagonist Radioligand) Assay SKCa (Non-Selective) Rat Potassium Ion Channel [125I] Apamin Binding Assay hERG Human Potassium Ion Channel [3H] Astemizole Binding (Antagonist Radioligand) Assay DP2 Human Prostanoid GPCR Binding (Agonist Radioligand) Assay DP1 Human Prostanoid GPCR Binding (Agonist Radioligand) Assay EP1 Human Prostanoid GPCR Binding (Agonist Radioligand) Assay EP2 Human Prostanoid GPCR Binding (Agonist Radioligand) Assay EP4 Human Prostanoid GPCR Binding (Agonist Radioligand) Assay FP Human Prostanoid GPCR Binding (Agonist Radioligand) Assay Non-Selective Rat P2Y GPCR Binding (Agonist Radioligand) Assay RXRalpha Human Retinoid X NHR Binding (Agonist Radioligand) Assay Non-Selective Rat PDE [3H] Rolipram Binding (Antagonist Radioligand) Assay RY3 Rat Ryanodine Ion Channel Binding (Agonist Radioligand) Assay 5-HT1A Human Serotonin GPCR Binding (Agonist Radioligand) Assay 5-HT1B Rat Serotonin GPCR Binding (Antagonist Radioligand) Assay 5-HT2B Human Serotonin GPCR [3H]LSD Binding (Agonist Radioligand) Assay 5-HT2C Human Serotonin GPCR Binding (Antagonist Radioligand) Assay 5-HT3 Human Serotonin Ion Channel Binding (Antagonist Radioligand) Assay 5-HT4 Guinea Pig Serotonin GPCR Binding (Antagonist Radioligand) Assay 5-HT5A Human Serotonin GPCR Binding (Agonist Radioligand) Assay 5-HT6 Human Serotonin GPCR Binding (Agonist Radioligand) Assay 5-HT7 Human Serotonin GPCR Binding (Agonist Radioligand) Assay SET Human Serotonin Transporter Binding (Antagonist Radioligand) Assay sigma1 Human Binding (Antagonist Radioligand) Assay sigma2 Rat [3H] Ifenprodil Binding (Agonist Radioligand) Assay Non-Selective Rat Sodium Ion Channel [3H] Batrachotoxinin Binding (Site 2) Assay sst1 Human Somatostatin GPCR Binding (Agonist Radioligand) Assay sst3 Human Somatostatin GPCR Binding (Agonist Radioligand) Assay sst2 Human Somatostatin GPCR Binding (Agonist Radioligand) Assay sst4 Human Somatostatin GPCR Binding (Agonist Radioligand) Assay sst5 Human Somatostatin GPCR Binding (Agonist Radioligand) Assay TR (Non-Selective) Rat Thyroid Hormone NHR Binding (Agonist Radioligand) Assay TRH Rat Thyrotropin-RH GPCR Binding (Agonist Radioligand) Assay TGFbeta (Non-Selective) Mouse TKL Kinase Binding (Agonist Radioligand) Assay UT (GPR14) Human Urotensin GPCR Binding (Agonist Radioligand) Assay VIP1 (VPAC1) Human VIP and PACAP GPCR Binding (Agonist Radioligand) Assay VIP2 (VPAC2) Human VIP and PACAP GPCR Binding (Agonist Radioligand) Assay V1A Human Vasopressin / Oxytocin GPCR Binding (Antagonist Radioligand) Assay V1B Human Vasopressin / Oxytocin GPCR Binding (Agonist Radioligand) Assay V2 Human Vasopressin / Oxytocin GPCR Binding (Agonist Radioligand) Assay VDR Human NHR Binding (Agonist Radioligand) Assay OX2 Human Orexin GPCR Binding (Agonist Radioligand) Assay CysLT2 Human Leukotriene GPCR Binding (Agonist Radioligand) Assay IP Human Prostanoid GPCR Binding (Agonist Radioligand) Assay PR Human Progesterone NHR Binding (Agonist Radioligand) Assay EP3 Human Prostanoid GPCR Binding (Agonist Radioligand) Assay CT Human Calcitonin GPCR Binding (Agonist Radioligand) Assay OX1 Human Orexin GPCR Binding (Agonist Radioligand) Assay Histamine H4 Non-Selective Rat P2X Ion Channel Binding (Agonist Radioligand) Assay 2. Capable of testing the aforementioned five (5) compounds in all the assays described above in under tee (3) months' time. 3. Provide a comprehensive report with the results of the single-dose duplicate testing of each of the 5 compounds against the 174 targets. 4. Capable of furnishing all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to complete this work. 5. Possess all critical instrumentation necessary for this work. 6. Possess significant experience (i.e. more than 5 years) in the testing of small molecule compounds for activity against the panel of 174 targets. Anticipated Period of Performance: Within tee (3) months from award date and receipt of first batch of material. Other Important Considerations: Any data generated as a result of this work will be the property of NCATS. Capability Statement / Information Sought: Respondents must provide clear and convincing evidence of possessing the knowedge, skills, abilities and experience to successfully perform the requirements described in this announcement. Detailed past experience in implementing similar requirements to the requirement described in this announcement must be clearly delineated in any response provided. Respondents must provide clear and convincing documentation of their capability in providing analytical quality control and any other requirements and services specified in this notice. Respondents must provide a general overview of the respondents' opinions about the difficulty and /or feasibility of the potential requirement, and any information regarding innovative ideas or concepts. Respondents must also provide information in sufficient detail of the respondents' (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information.. Respondents must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The response is limited to fifteen (15) pages; the 15-page limit does not include the cover page, executive summary, resumes, or references, if requested. The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. The response to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must reference the announcement number and be submitted electronically to Mark McNally, Contract Specialist, at mark.mcnally@nih.gov, and copy Jeffrey Schmidt, Contracting Officer, at jeffrey.schmidt@nih.gov. The response must be received by the response date and time specified in this announcement. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).. 75N95019Q00111 Department of Health and Human Services National Institutes of Health
3/21/19, 5:06 PM